News & Updates

The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.

Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.

Clinicians in Singapore and Hong Kong appear to delay the initiation of clozapine for treatment-resistant schizophrenia (TRS) despite familiarity with treatment guidelines, as reported in a study.

Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.

In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

Close blood pressure (BP) monitoring and more intensive and combined antihypertensive therapy are needed when there is a high prevalence of uncontrolled arterial hypertension (AH) despite the successful coarctation of the aorta (CoA) correction and use of relatively low doses of antihypertensive drugs, suggests a recent study.

In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).